Equities Analysts Set Expectations for CTXR FY2026 Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Research analysts at HC Wainwright reduced their FY2026 earnings estimates for Citius Pharmaceuticals in a research note issued to investors on Wednesday, August 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($2.03) per share for the year, down from their previous forecast of ($1.87). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.31) EPS and FY2027 earnings at ($1.44) EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $5.46 million.

Other research analysts have also recently issued reports about the company. Wall Street Zen cut Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Zacks Research upgraded Citius Pharmaceuticals to a “hold” rating in a research note on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Citius Pharmaceuticals has an average rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Price Performance

CTXR stock opened at $0.60 on Friday. The stock has a 50-day moving average price of $0.59 and a two-hundred day moving average price of $0.69. Citius Pharmaceuticals has a 1 year low of $0.47 and a 1 year high of $2.19. The stock has a market cap of $16.47 million, a PE ratio of -0.36 and a beta of 1.03. The company has a current ratio of 0.84, a quick ratio of 0.16 and a debt-to-equity ratio of 0.08.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CTXR. XTX Topco Ltd bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at about $32,000. NewEdge Advisors LLC bought a new position in Citius Pharmaceuticals during the second quarter worth about $40,000. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals during the fourth quarter worth approximately $46,000. BlackRock Inc. bought a new stake in Citius Pharmaceuticals in the second quarter valued at approximately $42,000. Finally, Heights Capital Management Inc. bought a new position in shares of Citius Pharmaceuticals during the 4th quarter worth approximately $622,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.